摘要
Although the abnormal expression of miRNAs in cancer cells is a widely accepted phenomenon, the molecular mechanisms underlying miR-3648 progression and metastasis in gastric cancer (GC) remain unclear. miR-3648 expression is downregulated and its ectopic expression in GC cells significantly suppressed cell proliferation and metastasis. Mechanistic analyses indicated that miR-3648 directly targets FRAT1 or FRAT2 and inhibits FRAT1- or FRAT2-mediated invasion and motility in vitro and in vivo. Moreover, FRAT1 physically interacted with FRAT2. Furthermore, FRAT1 overexpression promoted GC cell invasion, whereas siRNA-mediated repression of FRAT2 in FRAT1-overexpressing GC cells reversed its invasive potential. Besides, miR-3648 inactivated the Wnt/beta-catenin signalling pathway by downregulating FRAT1 and FRAT2 in GC. Interestingly, c-Myc, a downstream effector of Wnt/beta-catenin signalling, was also downregulated by miR-3648 overexpression. In turn, c-Myc negatively regulated miR-3648 expression by binding to the miR-3648 promoter. In addition, miR-3648 expression levels were negatively correlated with c-Myc, FRAT1, and FRAT2 expression in fresh gastric samples. Our studies suggest that miR-3648 acts as a tumour-suppressive miRNA and that the miR-3648/FRAT1-FRAT2/c-Myc negative feedback loop could be a critical regulator of GC progression.
学科与关键词
- MiR-4268 suppresses gastric cancer genesis through inhibiting keratin 80Zhang, Fan; Wang, Guoxian; Yan, Wenjuan; Jiang, Hongmei*CELL CYCLE, 2022, 21(19): 2051-2064.被引 2
- miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-mycHe Weiling; Li Yuhuang; Chen Xinlin; Lu Liya; Tang Bin; Wang Zhixiong; Pan Yunbao; Cai Shirong; He Yulong*; Ke ZunfuJournal of Gastroenterology and Hepatology, 2014, 29(7): 1427-1434.被引 12
- c-Myc-activated intronic miR-210 and lncRNA MIR210HG synergistically promote the metastasis of gastric cancerLi, Zhi-Yong; Xie, Ying; Deng, Mingxia; Zhu, Leqing; Wu, Xiaobin; Li, Guangqiang; Shi, Nan-Xi; Wen, Chuangyu; Huang, Weicai; Duan, Yuanyuan; Yin, Zhinan*; Lin, Xue-Jia*Cancer Letters, 2022, 526: 322-334.被引 22
